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Abstract: The aim of this narrative review is to introduce the reader to Bayesian methods that, in our
opinion, appear to be the most important in the context of rare diseases. A disease is defined as
rare depending on the prevalence of the affected patients in the considered population, for example,
about 1 in 1500 people in U.S.; about 1 in 2500 people in Japan; and fewer than 1 in 2000 people in
Europe. There are between 6000 and 8000 rare diseases and the main issue in drug development is
linked to the challenge of achieving robust evidence from clinical trials in small populations. A better
use of all available information can help the development process and Bayesian statistics can provide
a solid framework at the design stage, during the conduct of the trial, and at the analysis stage.
The focus of this manuscript is to provide a review of Bayesian methods for sample size computation
or reassessment during phase II or phase III trial, for response adaptive randomization and of for
meta-analysis in rare disease. Challenges regarding prior distribution choice, computational burden
and dissemination are also discussed.
Keywords: Bayesian; rare disease; prior distribution; meta-analysis; sample size
1. Introduction
A disease is defined as rare depending on the prevalence of the affected patients in
the considered population. In the United States, a disease is rare if it affects fewer than
200,000 people in the U.S. [1] (or about 1 in 1500 people); in Japan, if it affects fewer than
50,000 patients in Japan (or about 1 in 2500 people); and in the European Union if the
prevalence is no more than 5 per 10,000 (that is, fewer than 1 in 2000 people), but the
definition excludes diseases that are not also life-threatening, chronically debilitating,
or inadequately treated [2]. There are between 6000 and 8000 rare diseases [3], 71.9% of
which are genetic and 69.9% which exclusively affect paediatric populations, and it is
estimated that the global population prevalence of rare diseases is of 3.5–5.9%, which
implies that 263–446 million persons are affected at any stage in their life [4]. The usual
level of rigorous clinical trial evaluation of treatments is required in rare diseases just as
much as in more common ones. Although in some cases, particularly in phase II trials,
single-arm trials might be considered (see, for example, Grayling et al. [5]), randomized
controlled trials are to be preferred when this is possible. For example, the European
regulatory guidance [2] affirms that “patients with [rare] conditions deserve the same
quality, safety and efficacy in medicinal products as other patients; orphan medicinal
products should therefore be submitted to the normal evaluation process"; this is also in
agreement with U.S. guidance [6].
The main issue in drug development for rare diseases is linked to the challenge of
achieving robust evidence from clinical trials in small populations when trial sample
sizes are necessarily limited [7]. Even if for some rare diseases the population size is
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relatively large (for instance, Friedreich Ataxia in the EU) [8], the majority of rare dis-
eases are less frequent [9]. Small population clinical trials have been the focus of much
methodological research activity in the last two decades. From a regulatory perspec-
tive, the European Medicines Agency (EMA) described a methodological framework,
summarizing several possible approaches, in the guidance “Guideline on Clinical Trials
in Small Populations” [10] and the Food and Drug Administration (FDA) in the draft
guidance on rare disease [6]. The European Union’s Seventh Framework Programme
for Research, Technological development and Demonstration (EU FP7), acknowledging
the need for additional methodological research work, funded three projects in 2013;
the Integrated Design and Analysis of Small Populations Group Trials (IDeAl) project
(www.ideal.rwth-aachen.de), the Innovative Methodology for Small Populations Research
(InSPiRe) project (www.warwick.ac.uk/inspire), and the Advances in Small Trials Design
for Regulatory Innovation and Excellence (Asterix) project (www.asterix-fp7.eu) [8,11–13].
The drug development process involves on-going learning as data are observed
through the series of clinical trials, and, above all in rare diseases, there is a considerable
effort to optimize this learning process [14,15]. A better use of all available information can
help the process and Bayesian statistics provides an opportunity to do this in a formal way
(at the design stage, during the conduct of the trial, and at the analysis stage) [16,17]. Like
drug development, the Bayesian approach can be seen as an on-going learning process:
it starts with a prior belief (quantified as a prior distribution for the unknown model
parameters), which is then updated with the new evidence (likelihood data from the
new trial/experiment) to yield a posterior belief (expressed as a posterior probability
distribution for the unknown model parameters). In this way, Bayesian statistics provides
a mathematical method for calculating the predictive probabilities of future events, given
the actual trial and the knowledge from prior trials. Moreover, a formal Bayesian analysis
can incorporate different utilities or prior beliefs coming from different stakeholders and
quantify how these could impact potential decision-making.
Bayesian methods and designs are well established and mostly accepted, by both
clinicians and regulatory agencies, in early phase clinical trials. Due to the greater flexibility,
in both design and analysis, of the Bayesian paradigm with respect to the frequentist one
and since type I and II errors do not have to be controlled at this stage, Bayesian adaptive
designs are mostly chosen for these stages [18]. As early phase trials in all diseases
use small sample sizes, designs, specifically developed for rare diseases are unnecessary.
Thus, in this manuscript we will focus on novel Bayesian approaches firstly developed
for confirmatory/randomized trials in the rare disease setting, where more conventional
approaches may be unfeasible.
The aim of this narrative review is to show to the reader Bayesian methods that, in our
opinion, appear to be the most important in the context of rare diseases. Its purpose is
not to present a comprehensive compendium of Bayesian statistics in rare diseases, but to
give a starting point for the reader on some uses of novel Bayesian methods in this field.
All methods are presented in a general way, without mathematical formalism, so that a
reader who already have a basis of Bayesian statistics can understand the general idea,
along with the corresponding principal(s) reference(s), in such a way the reader can find
the details for methods they wish to explore in more detail. In the following sections,
three specific topics dealing with the application of a Bayesian design are introduced.
The first topic, in Section 2, regards methods for sample size computation or reassessment
during randomized phase II or phase III trial. The second topic, a recent method proposed
for response adaptive randomization, is presented in Section 3. Section 4 presents the
fourth topic of Bayesian meta-analysis methods developed for evidence combination in
rare diseases. Finally, we discuss frequent challenges faced when choosing a Bayesian
design; in particular, the priors distributions choice, which include the issue of the quan-
tity of information and commensurability between prior information and actual data;
the computational burden required; and dissemination issues.
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2. Sample Size Determination/Re-Estimation
Usual sample size determination approach focus on frequentist properties, that is,
type I error and study power. However, in a rare disease setting, accruing the number of
patients required to perform a fully-powered significance test after the trial may be infeasi-
ble. Increasing the allowed type I error can be a solution to reduce the required sample
size. However, as recalled in the introduction, this practice is not generally supported by
regulatory agencies. As an alternative, some authors have proposed the use of a Bayesian
decision-theoretic framework [19]. A Bayesian decision-theoretic approach can be applied
when we would like a treatment recommendation not based on type I error but on maximiz-
ing an expected gain for the total population. According this approach, we can compare the
costs of clinical trial evaluation with the potential benefits to current and future patients,
assessing how the cost-benefit balance differs between large and small patient populations
when, in the latter, patients recruited to a clinical trial could be a substantial proportion
of the population. The design of the study, including the sample size, can then be chosen
on the basis of the expected gain, with the sample size that maximizes the expected gain
chosen for the clinical study. Here the concept of a “gain” is interpreted very broadly and
can be defined from the patient, sponsor, regulatory, public health, or society perspective,
or from a combined perspective. Stallard et al. [20] have shown that for a wide range of
distributions, including those for continuous, binary or count responses, and gain function
forms, the optimal trial sample size is proportional to the square root of the population
size, with the constant of proportionality depending on the gain function form and prior
distribution of the parameters of the distribution of the data. A smaller sample size may
thus be appropriate for a trial in a rare disease than in a more common one.
Bayesian statistics can also be adopted to overcome some challenges in the calculation
of sample sizes from the frequentist perspective. For example, for normally distributed
outcomes, values for variances need to be specified, but, especially in the case of small
populations, may be based on very little information, for example, that from only one very
small pilot study. When using a Bayesian approach, the aggregation of prior information on
the variance with newly collected data is more formalized. Brakenhoff et al. [21] proposed
a framework incorporating the employment of power priors in order for operational
characteristics to be controlled in case of prior-new data conflict.
Bayesian group sequential designs could also be used to provide interim stopping
criteria, based on efficacy and/or futility. Even if the frequentist operating character-
istics of these designs are usually checked, they are not designed to optimize them.
A practical guide for their implementation and reference for software can be found in
Gsponer et al. [22].
3. Response Adaptive Randomization
While randomization is the established method for obtaining scientifically valid treat-
ment comparisons in clinical trials, as the trial progresses, increasing evidence may suggest
that one study group is responding or doing much better than another. As a consequence,
novel randomization methods, such as response adaptive randomization [23] (RAR), have
been proposed to address this ethical question continuously updating assignment prob-
abilities based on response of the different groups to their respective treatments so as to
allocate more patients to better-performing treatments. Both, frequentist and Bayesian
approach can be applied, however, the latter one has gained more popularity due to its
flexibility [24,25]. In the same manner as the previous decision theoretic idea, this approach
could be considered in rare disease setting, where future patients in the general population
is limited, to balance the benefits to current trial patients and future ones. Nonetheless,
standard adaptive randomization may lead to estimation bias [26], with the potential for
the trial to reach an erroneous conclusion. Therefore, novel and calibrated RAR approaches
should be preferred. The small sample sizes in trials in rare diseases may also mean that it
is possible to calibrate RAR methods in a way that would be infeasible in larger trials.
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A recent paper suggests a novel randomized response-adaptive design specifically
developed for a rare disease trial [27]. It uses the framework of finite-horizon Markov
decision processes and dynamic programming (DP) to recruit more patients to the more
beneficial arms while guaranteeing a minimum sample size to each treatment arm. The au-
thors show that the design has good operating characteristics, in term of (i) the percentage
of patients allocated to the superior arm, which is much higher than in the traditional fixed
randomized design; (ii) the power, which is higher than optimal DP; and (iii) bias and
mean square error of the treatment effect estimator, which are small.
4. Meta-Analysis
Meta-analyses are used to combine evidence from multiple studies. Differences in
study characteristics, such as trial design and study populations, can bring to heteroge-
neous treatment effects and these must be accounted for in the meta-analysis formulation.
To deal with the between-trial heterogeneity, random-effects meta-analysis has become
the gold standard, and the most used method is the normal–normal hierarchical model
(NNHM) [28]. In a rare disease, the limited number of trials and their small sample size
may impact the validity of usual frequentist meta-analysis methods. A Bayesian approach
offers another way to perform random-effect meta-analyses within the NNHM framework.
One of the advantages is that the solution remains coherent for small numbers of studies,
although careful prior specification is required. Friede et al. [29] showed that, when doing
meta-analysis with only two studies, Bayesian random-effects meta-analyses with priors
covering plausible heterogeneity values offer a good compromise. They compared the
Bayesian method to the NNHM, to the Hartung-Knapp-Sidik-Jonkman method (HKSJ) and
to the modified Knapp-Hartung method (mKH). On one hand, the coverage of the standard
method, based on normal quantiles, was unsatisfactory; on the other hand, very large
(therefore uncertain) confidence intervals resulted from the HKSJ and mKH. An acceptable
trade-off between these two extremes was achieved, in general, by Bayesian intervals that
showed suitable characteristics. Usually, the Bayesian approach is computationally more
demanding. However, optimized free software are available, such as the bayesmeta R
package, which uses a general semi-analytical approach to solve the meta-analysis problem
via the DIRECT approach [30] and provides an efficient and user-friendly interface to
Bayesian random-effects meta-analysis [31].
When dealing with binary outcomes, the binomial-normal hierarchical model is usu-
ally preferred to the NNHM, which then relies on asymptotic approximations. A challenge
in this setting in rare diseases is that we could face the probability to have no events due
to the small sample sizes. Frequentist approaches are known to induce bias and to result
in improper interval estimation of the overall treatment effect in a meta-analysis with
zero events [13]. On the other hand, Bayesian models are known for being sensitive to
the choice of heterogeneity prior distributions in sparse settings, therefore, the need to
identify priors with robust properties is crucial. Pateras et al. [32] proposed a general way
to set prior distributions. Via simulations, they showed that a uniform heterogeneity prior,
bounded between -10 and 10, on the log heterogeneity parameter scale shows appropriate
95% coverage and induces relatively acceptable under/over estimation of both the overall
treatment effect and heterogeneity, across a wide range of heterogeneity levels.
The Bayesian meta-analysis approach also allows implementation of a number of more
advanced analysis strategies. A series of studies may be used to inform the analysis when
the focus is not on an overall synthesis, but rather on a particular study that is to be viewed
in the light of previously accumulated evidence. For example, Wandel et al. [33] used a
Bayesian meta-analytic approach to inform a phase III study with phase II data. They
investigated the use of shrinkage estimates to support data from a single trial in the light
of external information. The method allows quantifying and discounting the phase II data
through the predictive distribution relevant for phase III. Bayesian meta-analysis approach
can also be adapted to incorporate external information from historical controls [34] or
borrow information from other arms in a randomized control trial, for example, in a basket
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design [35,36]. Such approaches could prove very valuable in the setting of rare diseases
where trials are necessarily small.
5. Challenges
As stated above, the Bayesian approach can be more flexible than the frequentist
counterpart. However, the flexibility comes along with a number of possible challenges.
Even if Bayesian methods can bring substantial benefits, their validity and effectiveness
require expertise and care. In the following, we will describe some points that should be
addressed when planning a Bayesian analysis.
5.1. Prior Distributions Choices
In Bayesian statistics, external information can be easily incorporated into the prior
distributions. An informative prior distribution for the unknown parameters could be
determined through elicitation of expert knowledge, from data from other trials or from
a search of the literature to identify results obtained in trials of similar drugs, or the
same drug in a different population, via the so called “extrapolation". Extrapolation
approaches are well known in paediatrics, where the proper dosage for children is estimated
starting from adults’ data, and in bridging studies, where the drug is tested in a new
geographical population, for example, in Asian, given the results in a previous one, for
example, Caucasian. This concept can be translated in rare disease, since rare diseases
prevalence may vary by continent (i.e., IgA nephropathy is rather rare in the EU but more
frequent in Asia and Africa) and we can be to adopt proofs of efficacy from the larger
populations to the smaller one [8].
However the prior distribution is obtained, the use of an informative prior to make
inferences about medical treatments based on small sample size trials remains inherently
controversial, however. Choice of a prior distribution must therefore be done carefully,
since the use of informative priors may be seen as introducing bias into posterior inferences
and inflating type I error rates. This is a general problem common in many different
fields, and several authors have addressed the issue of eliciting experts’ opinions, building
priors upon the elicited values, and performing Bayesian analyses using the resulting
priors. See O’Hagan et al. [37] for a complete review. The elicitation needs to be made
as meticulous and objective as possible to catch expert expertise. One way is to follow a
recognized protocol that is designed to address and minimize the cognitive biases [38].
In the following, we summarize two approaches that have already been used in the context
of rare disease.
The first approach describes how to obtain a consensus between experts. This research
was motivated by the design of the MYPAN trial, a multicentre RCT comparing mycophe-
nolate mofetil (MMF) with cyclophosphamide (CYC) for the treatment of polyarteritis
nodosa, a rare and serious inflammatory blood vessel disease in children [39]. The authors
proposed to add priors on the probability of success of one arm and on the log-odds ratio
of the probabilities. Then, a behavioral aggregation process, by which experts interact to
reach a mutually agreeable consensus through constructive discussions, was chosen for
systematic elicitation from clinicians of their beliefs concerning treatment efficacy. In par-
ticular, experts’ individual prior beliefs were obtained at the beginning of the process;
then, the full group was asked to reach a consensus. The results are then used to establish
Bayesian priors for unknown model parameters and the authors have also considered the
possibility of considering results from related trials. A similar strategy was used in a trial
of adalimumab versus pamidronate for children with CNO/CRMO [40].
The second approach focuses on reflecting, when eliciting experts’ opinions, how
these depend on differences in experience, training and medical practice [41]. Motivating
by a 70-patient randomized trial to compare two treatments (the same described in the first
approach) for idiopathic nephrotic syndrome in children (NCT 01092962), the authors pro-
posed a Bayesian methodology for constructing a bivariate parametric prior starting from
elicited graphical information. The method involves four steps: (i) each physician builds
Int. J. Environ. Res. Public Health 2021, 18, 1022 6 of 9
manually two histograms, one for each treatment parameter using the “bins-and-chips”
graphical method of Johnson et al. [42]; (ii) then, for each physician and each treatment
parameter, a marginal prior, characterized by location and precision hyperparameters,
is fitted to the elicited histogram; (iii) a bivariate prior is built by averaging the marginals
over a latent bivariate distribution; (iv) finally, an overall prior is obtained as a mixture of
the individual physicians’ priors. The approach also suggests a framework for performing
a sensitivity analysis of posterior inferences to prior location and precision.
Incorporating external information, whatever the source type (other trial, experts’
elicitation, etc.), has to be done properly, as the information can be in conflict with the
actual data or the amount of information can overwhelm trial data. Several methods that
allow prior information to be incorporated if it is in accordance with the trial data and
otherwise to be down-weighted have been proposed [34,43,44]. Moreover, the effective
sample size allows to quantify the information in the prior to be specified in term of the
number of hypothetical patients used to build the prior [45]. Different prior building
approaches may be used for different parameters; for example, historical control can
be included via a power prior approach and experts’ opinion can be used for the new
treatment effect. An adaptation of the power prior approach, that is useful particularly for
borrowing evidence from a single historical study, was proposed in rare disease setting [46].
Borrowing information from a historical trial is often related the type I error inflation.
By determining the amount of similarity between the new and historical data, this method
uses predictive probabilities and is parameterized in order to control the type I error.
5.2. Computational Burden
Estimation of posterior distributions can be challenging when prior distributions do
not have simple conjugate forms. Specific Markov chain Monte Carlo algorithms, such as
the Gibbs sampling or the Hamiltonian Monte Carlo, can be used to obtain an approxi-
mation of posteriors. Even if freely available software and the increasing computational
power of computers may help the Bayesian implementation, writing, coding and testing
the models usually requires a bigger effort than choosing a frequentist approach. In general,
the more complex the model or the prior distribution, the longer the computational time to
obtain the result. Validation of the method via simulation is one of the common way used
in Bayesian setting. Simulating several possible scenarios can allow the user to calibrate
model parameters (i.e., the quantity of information in the prior distribution) to obtain
desired operational characteristics, such as the type I error control or the power. Choosing a
fast and reliable approximation method is, however, crucial when simulations are required.
5.3. Dissemination
Even if the Bayesian approach has been shown to capture the thinking behavior of
clinicians [41], Bayesian methods and results are sometimes still viewed with suspicion
by clinicians and traditional statisticians. The influence of the prior distribution may be
considered disturbing and the lack of p-values can give the feeling that regulatory agencies
will not consider the results obtained. In effect, Bayesian methodologies are usually less
discussed in public regulatory guidelines than the frequentist counterpart. However, the
FDA Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials [47]
shows the regulatory agencies efforts in this direction. The guidance gives several Bayesian
insights that could be used in general, not only in medical device field. Several sections
explain how to well plan a Bayesian clinical trial, what to consider when choosing prior
distributions, and how to analyze the data. Then, in the technical details sections, the FDA
points out the importance of simulations to obtain operating characteristics of the planned
design, to assess the type one error rate, power, etc. While also other recommendations
for Bayesian analyses have been developed [17,48,49], they were primarily addressed to
researchers, not to readers unfamiliar with Bayesian approaches [50]. Therefore, efforts are
needed to well explain the Bayesian philosophy to non-statisticians. An example is given in
Ferreira et al. [51] and Ferreira et al. [50], where the authors help clinicians interpretation
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of Bayesian clinical trial though a side-by-side comparison with the frequentist approach.
On one hand, they teach how to transfer frequentist ideas, such as the p-values or hypothe-
ses testing, to the Bayesian framework, such as posterior probabilities and Bayes factor, and,
on the other hand, they give insights on what to check when reading a Bayesian report.
6. Conclusions
The aim of this article has been to review the use of Bayesian methods in confirmatory
trials in rare diseases, though many of the approaches described could also be applied in
clinical trials in other more common disease areas.
The formal Bayesian approach permits the incorporation of accumulating information
into the analysis of the actual trial and, therefore, the updating of belief. This feature
is extremely attractive in rare disease setting, where usually sample sizes and the op-
portunities to performs clinical trials are limited. Incorporation of previous information
should be strongly considered and the Bayesian approach, with its flexibility, could be
seen as a future gold standard in this field. As shown in the manuscript, the accumulated
information can be used in the prior distribution settings, in sample size optimization
and/or in randomization. Depending on the trial, where and when using this kind of
information is used has to be carefully chosen and simulations are strongly suggested to
evaluate method performances.
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DP dynamic programming
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FDA Food and Drug Administration
HKSJ Hartung-Knapp-Sidik-Jonkman method
mKH modified Knapp-Hartung method
MMF mycophenolate Mofetil
NNHM normal-normal hierarchical model
RAR response adaptive randomization
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